NH had previously indicated that the expense for BE studies for SequestOx was prohibitive. Now that the company has a war chest including cash on hand plus a nice bank loan, they can proceed to compete the protocol for acceptance. The FDA waiver of the substantial filing fee is a big deal for shareholders.
If an when he announces a successful study, the stock will again be in play. Bargain prices will not be around much longer.
Thanks for alerting the board with important information. your title is well deserved. Hail to the King.
News 
Market Data 
Discover 
AI
